Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
84 participants
INTERVENTIONAL
2008-08-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a randomized placebo controlled (RCT) double blind study, to evaluate the efficacy of thalidomide in inducing clinical remission at 8 weeks in refractory IBD patients aged 2-20 years.
The primary hypotheses of the study is that thalidomide would be more effective than placebo in inducing clinical remission.
The RCT phase is followed by a open-label phase, to further evaluate efficacy and safety of thalidomide in thalidomide responders, with a total follow up of one year.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Although onset is most common in the third decade of life, more than one third of IBD cases are diagnosed before age sixteen, and these younger patients, especially with Crohn's disease, are increasing in Western countries. Recent studies in the United Kingdom, Sweden and the United States report an incidence of 5-7 new cases of IBD every year per 100,000 subjects \< 16 years of age, with an increasing trend over the last two decades.
IBD-related morbidity causes special concern in childhood-onset cases, since the disease can compromise height and weight development. This is even worsened in patients with poor disease control, which need steroid treatment in multiple courses and/or for a long period of time.
There are various drugs and treatments available for the management of IBD, but some patients, during the course of the illness, become resistant to conventional treatment, or develop serious adverse effects to immunosuppressive drugs.
A particular challenge is represented by those patients (especially children) who fail to respond to conventional treatment, or are steroid-dependent, or suffer from serious side effects from steroids use.
Thalidomide was first marketed in the early 1960s as a sedative drug and sadly gained notoriety because of its teratogenic effect. After few years from this tragedy, thalidomide was rediscovered both as an immunomodulator and as an anti-inflammatory drug, with anti tumor necrosis factor-alfa properties.
Thalidomide is now approved for the treatment of multiple myeloma and erythema nodosum leprorum. It has also been tested, with beneficial effects, in a variety of inflammatory diseases, especially those involving the skin and mucous membranes: recurrent aphthous stomatitis, oral and oesophageal ulcers in HIV, oral and genital ulcers and intestinal symptoms in Behcet's syndrome, graft versus host disease, skin manifestations in systemic lupus erythematosus, sarcoidosis, and tuberculosis. In these diseases, especially in those cases resistant to conventional treatments, thalidomide seems to have a promising role as a secondary therapeutic option.
The safety and efficacy of thalidomide in IBD has been recently evaluated in several open-label studies both adults and children, some of which with a long-term follow up. A total of approximately 200 patients with steroid-resistant or steroid-dependent IBD were treated with thalidomide. Overall, the drug was effective in inducing clinical remission in 20-70% of patients (average of 40%). 60-100% patients (average of 70%) had some clinical response. Steroid-tapering was possible in 60-100% of cases.
The most frequent side effect of thalidomide in IBD cases was neuropathy, which mainly reported as cumulative dose-dependent. Other possible side effects are constipation, sedation, dermatitis, mood disturbance, vertigo, cephalea, hypertension, hormonal alterations.
In the experience of our center, thalidomide was effective in achieving clinical remission in several children, adolescents, and young adults with intractable IBD. From 1998 to 2004 twenty-eight patients with refractory moderate-severe IBD (19 CD, 9 UC) received thalidomide 1.5-2.5 mg/kg/day. Remission was achieved with thalidomide in 21 of 28 (75%) patients (17 with CD, 4 with UC). Mean duration of remission was 34.5 months. Sixteen of 20 (80%) patients suspended steroids. Reversible neuropathy occurred in seven of 28 (25%) patients, but only with cumulative doses over 28 g. Other side effects requiring thalidomide suspension were vertigo/somnolence (one case), and agitation/ hallucinations (one case).
The aim of this study is to evaluate the efficacy of thalidomide therapy in children, adolescents and young adults with refractory Crohn's disease (CD) and ulcerative colitis (UD), with a total follow up of one year.
The study is divided in two phases:
* Phase I: randomized placebo controlled double blind study, to evaluate efficacy of thalidomide in refractory IBD patients, at 8 weeks.
* Phase II: open-label study, to evaluate efficacy and safety of thalidomide in patients responders to Thalidomide in Phase I, with a total follow up of one year.
Analysis will be stratified for Crohn's disease and ulcerative colitis. Given the hypotheses that thalidomide will be effective in inducing clinical remission at 8 weeks in 60% of patients with Crohn's disease, and 55% of patients with ulcerative colitis, compared to 20% of patients with placebo, with a significance of 0.05% and a power of 80%, estimated needed sample size is of 124 patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Thalidomide
Thalidomide
Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
2
Placebo
placebo
placebo capsules
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Thalidomide
Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
placebo
placebo capsules
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Definition of patient with refractory disease:
* Patients with active disease despite steroid therapy (prednisone at a dose 2 mg/kg/die, maximum 60mg/day, or equivalent) for 8 weeks and/or an immunosuppressive of proven efficacy (azathioprine o 6-mercaptopurine for 4 months; methotrexate for 3 months; Infliximab at the dose of 5 mg/kg at week 0,2,6 weeks; cyclosporine at the dose of 2mg/kg/day for 4 weeks or 1 week at 1m/kg/day EV) or patients exhibiting intolerance to these drugs which prevent them from continuing treatment.
Exclusion Criteria
* Disease requiring immediate surgical intervention.
* Severe ulcerative colitis or toxic megacolon.
* Contraindications to using thalidomide (on-going pregnancy, neuropathy) .
* Any of the following conditions: active infection, stool culture positive for enteric pathogens, tumors, HIV, transplanted organ, or non-controlled disease of the kidney, liver, endocrine system, heart, blood, nervous system or brain.
* Patients being treated with other drugs as part of an experimental study.
* Patients treated with infliximab in the previous eight weeks.
2 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ospedale Meyer
OTHER
Pediatric Gastroenterology Unit, IRCCS Gaslini, Genoa.
UNKNOWN
Vittore Buzzi Children's Hospital
OTHER
University of Pisa
OTHER
University of Messina
OTHER
Università degli Studi di Brescia
OTHER
University of Trieste
OTHER
IRCCS Burlo Garofolo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alessandro Ventura
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alessandro Ventura, MD
Role: STUDY_CHAIR
IRCCS Burlo Garofolo
Marzia Lazzerini, MD
Role: STUDY_DIRECTOR
IRCCS Burlo Garofolo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anatomy and Hystology, Spedali Civili di Brescia, University of Brescia.
Brescia, Brescia, Italy
Department of Pediatrics, Ospedale Meyer.
Florence, Florence, Italy
Pediatric Gastroenterology Unit, IRCCS Gaslini.
Genoa, Genoa, Italy
Pediatric Gastroenterology Unit, University of Messina.
Messina, Messina, Italy
Department of Pediatrics, Ospedali Buzzi.
Milan, Milan., Italy
Gastroenterology and Hepatology, University of Pisa.
Pisa, Pisa, Italy
Unit of Biochemistry and Pharmacology, University of Triest.
Trieste, Triest, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, Ventura A. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther. 2007 Feb 15;25(4):419-27. doi: 10.1111/j.1365-2036.2006.03211.x.
Lazzerini M, Martelossi S, Magazzu G, Pellegrino S, Lucanto MC, Barabino A, Calvi A, Arrigo S, Lionetti P, Lorusso M, Mangiantini F, Fontana M, Zuin G, Palla G, Maggiore G, Bramuzzo M, Pellegrin MC, Maschio M, Villanacci V, Manenti S, Decorti G, De Iudicibus S, Paparazzo R, Montico M, Ventura A. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA. 2013 Nov 27;310(20):2164-73. doi: 10.1001/jama.2013.280777.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TAL-005414-20
Identifier Type: -
Identifier Source: org_study_id